Stability-Indicating RP-HPLC Method Development and Validation for Eltrombopag Olamine in the Presence of Impurities and Degradation Products. Robustness by Design of Expert Software
- 23 November 2022
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of AOAC INTERNATIONAL
- Vol. 106 (2) , 267-275
Abstract
Background: A simple and reliable HPLC method for determining impurities in eltrombopag olamine (ELO) film-coated tablets is not available. At the same time, there is no official monograph reported. The proposed research is targeted at the development of a stability-indicating method for determining impurities in ELO film-coated tablets and drug substances. Objective: To develop and validate a simple and effective HPLC method for determining impurities in ELO film-coated tablets and drug substances. Methods: All the impurities were separated using a reverse phase (RP)-HPLC system equipped with a Zorbax SB-Phenyl 150 mm × 4.6 mm, 3.5 µm, column with UV detection at 230 nm and a flow rate of 1.2 mL/min. The column temperature was maintained at 45°C. Results: The proposed method was validated as per current regulatory guidelines. The coefficient of correlation was found to be >0.999 for all impurities. The LOD and LOQ for ELO and all specified impurities were determined. The precision and accuracy were obtained for ELO and its related impurities. Intra- and inter-day RSD values were between 1.22 and 2.04%, and impurity recovery varied between 93.80 and 103.69%. The stability of standard and sample solutions was established for 24 h. Conclusions: As per recent guidelines, a stability-indicating method has been developed to determine the impurities in ELO film-coated tablets and drug substances. QbD-based robustness was performed and proved that the method was robust. Highlights: The proposed article is the first RP-HPLC method for determining impurities in ELO film-coated tablets and drug substances. The quality by design (QbD) concept was utilized to verify the method performance.Keywords
This publication has 14 references indexed in Scilit:
- A Quality by Design and green LC technique for the determination of mast cell stabilizer and histamine receptor antagonist (Olopatadine HCl) in multiple formulationsBiomedical Chromatography, 2022
- QBD-driven HPLC method of eltrombopag olamine: Degradation pathway proposal, structure elucidation, and in silico toxicity predictionJournal of Pharmaceutical and Biomedical Analysis, 2021
- Stability indicating analytical method development and validation of eltrombopag olamine in tablet dosage form by RP-UPLCJournal of the Turkish Chemical Society Section A: Chemistry, 2020
- A simple high‐performance liquid chromatography method development for Carbidopa and Levodopa impurities: Evaluation of risk assessment before method validation by Quality by Design approachSeparation Science Plus, 2020
- Stability Indicating UHPLC Method Development and Validation for Estimation of Eltrombopag and its Related Impurities in Tablet Dosage formOriental Journal of Chemistry, 2018
- Liquid chromatography–tandem mass spectrometric assay for eltrombopag in 50μL of human plasma: A pharmacokinetic studyJournal of Pharmaceutical and Biomedical Analysis, 2014
- Assessment of the Pharmacokinetic Interaction between Eltrombopag and Lopinavir-Ritonavir in Healthy Adult SubjectsAntimicrobial Agents and Chemotherapy, 2012
- Metabolism and Disposition of Eltrombopag, an Oral, Nonpeptide Thrombopoietin Receptor Agonist, in Healthy Human SubjectsDrug Metabolism and Disposition, 2011
- Eltrombopag increases plasma rosuvastatin exposure in healthy volunteersBritish Journal of Clinical Pharmacology, 2011
- Eltrombopag (Promacta), a Thrombopoetin Receptor Agonist for the Treatment of Thrombocytopenia: Current and Future ConsiderationsAmerican Journal of Therapeutics, 2010